CRA consultant Becky Davis recently presented “GLP-1s: Riding the Wave of Innovative Medications” at Asembia’s AXS25 Summit, which looked at the evolution of the GLP-1 category, and what might be in store for future payer management.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...